Favorable response to PD-1 inhibitor plus chemotherapy as first-line treatment for metastatic follicular dendritic cell sarcoma of the spleen: a case report

Jielang Li; Min Ren; Feng Bi; Ye Chen; Zhiping Li

doi:10.3389/fimmu.2023.1228653

Favorable response to PD-1 inhibitor plus chemotherapy as first-line treatment for metastatic follicular dendritic cell sarcoma of the spleen: a case report

Front Immunol. 2023 Aug 25:14:1228653. doi: 10.3389/fimmu.2023.1228653. eCollection 2023.

Authors

Jielang Li¹, Min Ren^{1

2}, Feng Bi³, Ye Chen^{1

2}, Zhiping Li^{1

2}

Affiliations

¹ Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
² Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
³ Division of Abdominal Cancer, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Abstract

Follicular dendritic cell sarcoma (FDCS) is an uncommon low-grade malignant sarcoma. For localized FDCS, surgery is the most commonly recommended therapy option. However, there is no standard treatment protocol for metastatic FDCS. Here, we present a 68-year-old female with primary spleen FDCS who had multiple peritoneal metastases. She was treated with sintilimab (PD-1 inhibitor) plus chemotherapy (epirubicin plus ifosfamide) as first-line treatment achieving partial response (PR) and a relatively long progression-free survival (PFS) of 17 months. This case suggests that PD-1 inhibitor plus chemotherapy as first-line therapy seem to be a promising treatment option for metastatic FDCS.

Keywords: PD-1 inhibitor; chemotherapy; follicular dendritic cell sarcoma; immunotherapy; sintilimab.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Dendritic Cell Sarcoma, Follicular* / drug therapy
Female
Humans
Immune Checkpoint Inhibitors / therapeutic use
Peritoneum
Sarcoma*
Spleen

Substances

Immune Checkpoint Inhibitors

Grants and funding

The work was supported by General Program of Sichuan Natural Science Foundation (2022NSFSC0846) and 1·3·5 project for disciplines of excellence - Clinical Research Incubation Project, West China Hospital, Sichuan University (21HXFH030) and 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYJC18048).